Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting Myeloid-Derived Suppressor Cells in Patients With Recurrent/Progressive Grade 4 Glioma: Phase 1 Trial of Sitagliptin

NCT07541781 is registered in ClinicalTrials.gov with Kailin Yang, MD, PhD as lead sponsor.

NCT NCT07541781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07541781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting Myeloid-Derived Suppressor Cells in Patients With Recurrent/Progressive Grade 4 Glioma: Phase 1 Trial of Sitagliptin
Lead sponsor
Kailin Yang, MD, PhD
Phase
Phase 1
Overall status
Recruiting
Start date
June 11, 2026
Completion date
June 11, 2030
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioma, grade 4 malignant glioma of brain (disorder), recurrent glioblastoma, recurrent glioma